Surgical Oncology Insight最新文献

{"title":"Efficacy of Yttrium90 transarterial radioembolization as a bridge to surgery in hepatocellular carcinoma","authors":"Amelia WH Wong ,&nbsp;Shirley Cheng ,&nbsp;Anthony Herrera ,&nbsp;Linda Wong","doi":"10.1016/j.soi.2025.100146","DOIUrl":"10.1016/j.soi.2025.100146","url":null,"abstract":"<div><h3>Background</h3><div>Yttrium90 transarterial radioembolization (TARE) is increasingly used for bridging or downstaging to liver transplant(LT) or resection(LR) despite a paucity of data. This study aims to illustrate its efficacy as a bridge to surgery.</div></div><div><h3>Methods</h3><div>HCC patients who received Y90 TARE as their first treatment in Honolulu, HI during 2012–2022 were identified. Wilcoxon, Kruskal-Wallis, and Fischer’s t-tests identified statistical significance.</div></div><div><h3>Results</h3><div>Of 137 patients identified, 29 had advanced disease (stage III/IV) and 68 were LR candidates with inadequate FLR. Y90 TARE downstaged 14 %(n = 5/37) potential LR and one advanced disease to surgery. Of 40 LT candidates, 22 % underwent transplantation: 26 %(n = 7/27) within Milan and 15 %(n = 2/13) within UCSF criteria underwent transplantation. Only 9(22 %) were ineligible due to tumor progression; larger tumor size was the only predictor (&gt;7.5 cm, p &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>Y90 TARE is an effective bridging therapy but most did not get transplanted for non-tumor reasons (comorbidities, substance abuse). Larger tumor burden and cirrhosis may impact its ability to downstage to resection.</div></div><div><h3>Synopsis</h3><div>This retrospective cohort study of 137 hepatocellular carcinoma patients demonstrates that Y90 TARE is able to successfully bridge 15–26 % of patients to transplantation and 14 % of previously unresectable patients to surgery however larger tumor size and cirrhosis appears to limit its efficacy. Y90 TARE has the potential to be an effective salvage therapy in medically fit individuals however a minority actually proceed to surgery, therefore further studies evaluating multi-modality therapies may improve the prospect of surgical intervention.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100146"},"PeriodicalIF":0.0,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143924574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From genes to glands: The genetic framework of parathyroid syndromes","authors":"Niranjna Swaminathan,&nbsp;Julia Adriana Kasmirski,&nbsp;Andrea Gillis,&nbsp;Brenessa Lindeman,&nbsp;Sophie Dream,&nbsp;Herbert Chen","doi":"10.1016/j.soi.2025.100143","DOIUrl":"10.1016/j.soi.2025.100143","url":null,"abstract":"<div><div>Primary and secondary disorders of parathyroid hormone (PTH) secretion including primary hyperparathyroidism (PHPT) and hypoparathyroidism can result from both sporadic and hereditary causes. Advances in molecular genetics have expanded our understanding of the genetic syndromes underlying these disorders. This review aims to summarize the genetic landscape of hereditary parathyroid disorders, highlighting their molecular mechanisms, clinical presentations, diagnostic challenges, and management implications. We synthesized evidence from published literature and genetic testing guidelines issued by major endocrine societies. Specific focus was given to syndromes such as Multiple Endocrine Neoplasia, Hyperparathyroidism-Jaw Tumor (HPT-JT), Familial Isolated Hyperparathyroidism (FIHP), and Autosomal Dominant Hypocalcemia (ADH), among others. While 95 % of PHPT cases are sporadic, a small but clinically significant proportion is linked to germline mutations in genes such as MEN1, RET, CDC73, and CASR. Hypoparathyroid syndromes, though less common, are genetically diverse, involving genes related to parathyroid development, hormone secretion, and calcium-sensing. Current guidelines recommend genetic testing based on early age of onset, multiglandular disease, family history, and associated tumors. As genetic testing becomes more accessible, a precision medicine approach incorporating molecular diagnostics and counseling will play a central role in optimizing patient outcomes.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100143"},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143924575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitomycin C in HIPEC: A proposal to use abdominal cavity volume for drug dosage","authors":"George I. Salti ,&nbsp;Isabella D. Salti ,&nbsp;Aslam Ejaz ,&nbsp;Shankar Logarajah","doi":"10.1016/j.soi.2025.100142","DOIUrl":"10.1016/j.soi.2025.100142","url":null,"abstract":"","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100142"},"PeriodicalIF":0.0,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143923229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver resection that is less extensive than segmentectomy for hepatocellular carcinoma focused on the fourth branch of the portal vein","authors":"Shingo Shimada ,&nbsp;Hiroyuki Takahashi,&nbsp;Shoichiro Mizukami,&nbsp;Yuki Adachi,&nbsp;Koji Imai,&nbsp;Hideki Yokoo","doi":"10.1016/j.soi.2025.100140","DOIUrl":"10.1016/j.soi.2025.100140","url":null,"abstract":"<div><h3>Background</h3><div>The optimal location of the portal branch to be removed by liver resection that is less than a segmentectomy for patients with hepatocellular carcinoma (HCC) is elusive. This study examines the impact of removing the fourth branch on postsurgical outcomes.</div></div><div><h3>Methods</h3><div>HCC patients who underwent liver resection less extensive than segmentectomy (2015–2022) were included. The impact of removing the fourth branch of the tumor-bearing portal vein (PVR) on recurrence was evaluated using Gray and Fine-Gray methods, adjusted for confounding factors. Overall survival was assessed via the Kaplan-Meier method and log-rank test.</div></div><div><h3>Results</h3><div>Of the 89 patients eligible for this study, 47 were in the PVR group, and 42 were in the non-PVR group. The PVR group had a significantly lower median level of total bilirubin; however, other covariates related to liver function were comparable to those in the non-PVR group. Additionally, oncological and operative covariates were comparable between the two groups. The 1-, 3-, and 5-year cumulative incidences of recurrence were significantly lower in the PVR group than in the non-PVR group (10.9 %, 34.1 %, and 43.2 % vs. 21.6 %, 59.1 %, and 71.1 %, respectively; P = 0.01). The overall survival rates were comparable between the groups. Bivariable analysis was adjusted for recurrence using significant covariates identified by the univariable analysis and revealed that non-PVR surgery was associated with a significantly greater risk of HCC recurrence with any combination of other significant factors.</div></div><div><h3>Conclusions</h3><div>The risk of short-term intrahepatic recurrence may be reduced by liver resection via removal of the fourth branch of the portal vein.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100140"},"PeriodicalIF":0.0,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143783068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DOTATATE PET CT tumor volume as a predictor of surgical outcome in patients with metastatic gastroenteropancreatic neuroendocrine tumors","authors":"Sara Abou Azar ,&nbsp;Joseph Tobias ,&nbsp;Nicholas Feinberg ,&nbsp;Daniel Appelbaum ,&nbsp;Yonglin Pu ,&nbsp;Frances Lee ,&nbsp;Jason L. Schwarz ,&nbsp;Jelani Williams ,&nbsp;Rachel Nordgren ,&nbsp;J. Michael Millis ,&nbsp;Chih-Yi “Andy” Liao ,&nbsp;Xavier M. Keutgen","doi":"10.1016/j.soi.2025.100141","DOIUrl":"10.1016/j.soi.2025.100141","url":null,"abstract":"<div><h3>Background</h3><div>Surgical debulking for metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is associated with increased progression-free survival (PFS) and overall survival (OS) in retrospective studies. It remains unclear, however, which patients benefit most from surgery. DOTATATE PET/CT tumor volume (TV) in metastatic GEP-NETs has been shown to correlate with PFS and OS. Herein, we investigate how TV impacts outcomes in patients undergoing surgical debulking for GEP-NETs.</div></div><div><h3>Methods</h3><div>A retrospective chart review was conducted of patients with pancreatic and small bowel NET (PNET/SBNET) who underwent surgical debulking at our institution from 2019 to 2022. All patients had an estimated liver debulking threshold of &gt; 90 % and only patients with preoperative ⁶⁸Ga or ⁶⁴Cu-DOTATATE PET/CT were included. TV was obtained using the MIM Encore workstation.</div></div><div><h3>Results</h3><div>71 patients with metastatic GEP-NETs (35 % PNET and 65 % SBNET) underwent liver debulking with 19 synchronous primary tumor resections. 42 patients had symptomatic disease. Patients were divided into 4 TV quartiles, ranging from 8.46 to 2000 mL. On cox proportional hazards modeling, tumor volume stratified by quartiles was not significantly associated with longer PFS (p = 0.250) over a median follow-up of 13 months (7−23). However, there was an increased risk for Clavien-Dindo Grade III and IV complications with higher TV quartiles (p = 0.008). SBNETs with carcinoid syndrome (p = 0.047) and those with more lesions debulked (p = 0.025) were more likely to have improvement in postoperative symptoms.</div></div><div><h3>Conclusion</h3><div>Patients with larger tumor burden on preoperative DOTATATE PET/CT should not be excluded from surgical intervention but may need to be counseled on higher risks of operative complications.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100141"},"PeriodicalIF":0.0,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143790977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Propensity score–weighted analysis of neoadjuvant therapy versus upfront surgical resection in patients with biliary tract cancers","authors":"Elsa Hallab ,&nbsp;Hanfei Qi ,&nbsp;Mark Yarchoan ,&nbsp;Christopher Shubert ,&nbsp;Jeffrey Meyer ,&nbsp;Kelly Lafaro ,&nbsp;Jin He ,&nbsp;William Burns ,&nbsp;Richard Burkhart ,&nbsp;Benjamin Philosophe ,&nbsp;Elie Ghabi ,&nbsp;Nilofer S. Azad ,&nbsp;Jane Zorzi ,&nbsp;Paige Griffith ,&nbsp;Amol Narang ,&nbsp;Ihab Kamel ,&nbsp;Kelvin Hong ,&nbsp;Christos Georgiades ,&nbsp;Robert Liddell ,&nbsp;Robert Anders ,&nbsp;Marina Baretti","doi":"10.1016/j.soi.2025.100139","DOIUrl":"10.1016/j.soi.2025.100139","url":null,"abstract":"<div><h3>Background</h3><div>Bile tract cancer (BTC) is a heterogeneous and aggressive malignancy with a poor prognosis. Surgical resection is the main potentially curative treatment, but only about 20–30 % of patients present with resectable disease. The benefit of neoadjuvant chemotherapy (NAC) in BTC remains controversial. We explored outcomes of patients with BTCs receiving NAC compared to those who underwent upfront surgical resection using a propensity score weighting approach.</div></div><div><h3>Methods</h3><div>We identified patients who underwent surgical resection for stage I-III BTC between 2019 and 2023 and were evaluated at the Johns Hopkins Liver Multidisciplinary Cancer Clinic (Liver MDC). Propensity score weighting (PSW) was used to balance groups. Groups were assessed for differences in pathological response, recurrence-free survival (RFS), and overall survival (OS). Hazard ratios (HRs) were estimated using the PSW Cox proportional hazard regression model.</div></div><div><h3>Results</h3><div>Among 56 BTC patients that fit the inclusion criteria, 34 underwent upfront surgery, and 22 received NAC. Patients receiving NAC were more likely to have higher risk disease compared to patients receiving upfront resection (77.3 % vs 23.5 %, p &lt; 0.001), including tumor size greater than 5 cm (45.5 % vs 11.8 %, p = 0.0221), lymph node involvement on staging imaging (50.0 % vs 23.5 %, p = 0.0495), and a trend towards higher mean CA19–9 at diagnosis (258.7 vs 87.7 U/mL, p = 0.179). In the univariate analysis, the NAC group showed a trend toward shorter RFS compared to the upfront surgery group (15.1 months; 95 % CI 10.3-not available (NA) versus 23.5 months; 95 % CI 15.5-NA, HR= 2.24; 95 % CI: 0.88–5.69, p = 0.082). No significant differences were seen for OS (36.5 months; 95 % CI 26.5-NA versus 48.2 months; 95 % CI 44.5-NA, HR= 1.53; 95 % CI: 0.51–4.64–5.69, p = 0.448). Following PSW multivariable Cox analyses, receipt of NAC was associated with a trend toward reduced risk of recurrence (HR 0.83; 95 % CI 0.24–2.87 p = 0.7651) and death (HR 0.66; 95 % CI 0.2–2.16 p = 0.4890), although no statistically significant differences were observed.</div></div><div><h3>Conclusion</h3><div>These findings suggest that NAC may provide benefit for patients with higher-risk BTCs, achieving outcomes comparable to upfront surgical resection. The similar pathological results between the two groups further support the potential efficacy of neoadjuvant approaches. However, prospective trials are essential to definitively establish the optimal sequencing of chemotherapy and surgery in this patient population.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100139"},"PeriodicalIF":0.0,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143839513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidisciplinary management of nonmetastatic locally advanced prostate cancer (T3-4N0M0)","authors":"Marcelo P. Bigarella ,&nbsp;John M. Floberg ,&nbsp;David Jarrard","doi":"10.1016/j.soi.2025.100137","DOIUrl":"10.1016/j.soi.2025.100137","url":null,"abstract":"<div><h3>Purpose of review</h3><div>In this review, the current literature available to patients and providers on the multidisciplinary management of nonmetastatic locally advanced prostate cancer (T3-T4N0M0) was reviewed. Topics include the definition of the disease, the distinction between nonmetastatic locally advanced prostate cancer and locally advanced prostate cancer defined by the EUA and high-risk prostate cancer by NCCN and AUA guidelines, the role of radiation therapy in addition to androgen deprivation therapy, the current role of surgery and lypmh node dissectionthe difference between adjuvant vs. salvage treatment for such patients. Although there are multiple curative treatment approaches for locally advanced prostate cancer, no consensus regarding the optimal treatment option exists.</div></div><div><h3>Recent findings</h3><div>Historically, the use of androgen deprivation therapy (ADT) and external beam radiotherapy (EBRT) has been used in locally advanced prostate cancer¹. More recently, retrospective observational data showed equivalent results for patients undergoing primary radical prostatectomy with radiation therapy reserved as an adjuvant or salvage treatment as needed, and better outcomes were seen after advances in patient selection which include improvements in staging imaging with mpMRI and PSMA PET^2,3. Adjuvant radiation based on adverse features on pathology has also come into dispute, with early salvage showing non-inferior oncological outcomes and a more favorable toxicity profile.</div></div><div><h3>Summary</h3><div>Until high-level evidence evaluating surgery versus EBRT plus androgen deprivation therapy (ADT) for locally advanced disease is available as a result of the ongoing trial SPCG-15, options for patients with locally advanced prostate cancer include local radiotherapy in combination with androgen deprivation therapy (level I evidence) and radical prostatectomy with pelvic lymph node dissection for well-selected patients. Early salvage radiotherapy is non-inferior to adjuvant radiation.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100137"},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival and morbidity following metastasectomy for stage IV melanoma in the era of systemic therapy: A multicenter retrospective cohort study","authors":"M.R. Jansen ,&nbsp;J.J. Bonenkamp ,&nbsp;M. Jalving ,&nbsp;L.B. Been ,&nbsp;B.L. van Leeuwen","doi":"10.1016/j.soi.2025.100138","DOIUrl":"10.1016/j.soi.2025.100138","url":null,"abstract":"<div><h3>Background</h3><div>Modern systemic therapies for stage IV melanoma often result in remarkable and durable responses. Consequently, the indications for surgical resection in stage IV melanoma patients are evolving and remain debated. This study examines the survival and morbidity following metastasectomy for stage IV melanoma in the era of systemic therapy.</div></div><div><h3>Methods</h3><div>A multicenter, retrospective cohort study was conducted at the University Medical Center Groningen and Radboud University Medical Center Nijmegen. Adult patients with stage IV (AJCC 8th) melanoma who received systemic therapy and had metastasectomy between 2010 and 2020 were included. Outcomes were overall survival (OS), progression-free survival (PFS), and morbidity following metastasectomy.</div></div><div><h3>Results</h3><div>Forty-four patients were included (median age 57 years; 54.5 % females). Twenty-five (56.8 %) patients underwent metastasectomy to achieve no evidence of disease and 19 (43.2 %) patients for symptomatic metastases. The most common procedures were small bowel segmental resections (38.6 %) and skin/soft tissue excisions (19.3 %). Postoperative complications occurred in seven (15.9 %) patients and were mostly treated conservatively. During a median follow-up of 139 months, mean OS was 92 months, and median PFS was 23 months. Patients who experienced at a least partial response to systemic treatment before metastasectomy (HR 0.24, <em>p</em> = 0.029) and had treatment from 2016 (HR 0.21, <em>p</em> = 0.004) had prolonged OS.</div></div><div><h3>Conclusions</h3><div>Metastasectomy in selected stage IV melanoma patients was associated with favorable OS, particularly in patients who had at least a partial response to systemic treatment prior to metastasectomy and had treatment from 2016. Postoperative morbidity was acceptable.</div></div><div><h3>Synopsis</h3><div>This study evaluates the survival and morbidity following metastasectomy for stage IV melanoma in the era of systemic therapy, revealing favorable outcomes, particularly in patients with at least a partial response to systemic treatment prior to surgery and who had treatment after 2016.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100138"},"PeriodicalIF":0.0,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143680943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"National disparity in guidelines for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis","authors":"Toshiyuki Kitai,&nbsp;Kenya Yamanaka","doi":"10.1016/j.soi.2025.100136","DOIUrl":"10.1016/j.soi.2025.100136","url":null,"abstract":"<div><div>Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS+HIPEC) improved survival in appropriately selected patients with peritoneal carcinomatosis. Guideline recommendations are important for its promotion. However, this treatment is not performed widely in Japan. The disparity in practice may be reflected in the national guidelines. Recommendations were compared between 5 sets of guidelines each in Western countries and Japan. 1) The role of CRS was established for colorectal and ovarian cancers whereas that of HIPEC was controversial in Western countries. On the other hand, neither was recommended for colon cancer, and HIPEC was recommended only in research for ovarian cancer in Japan. 2) Potential effects in a limited cases were recognized for gastric cancer in the Western guidelines. 3) Resection for localized metastasis for colon cancer and intraperitoneal chemotherapy for ovarian and gastric cancers were recommended in Japan instead of CRS+HIPEC. 4) CRS+HIPEC is recommended as a first-line treatment for pseudomyxoma peritonei and peritoneal mesothelioma in Western countries but recommended only for pseudomyxoma in Japan. There is a disparity in the guidelines for CRS+HIPEC, which is attributed to not being widely performed in Japan.</div></div><div><h3>Synopsis</h3><div>The disparity in practice may be reflected in the national guidelines for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Recommendations were towards to more negative in Japan than in Western countries. This is attributed to not being widely performed in Japan. It is necessary to achieve social consensus on this treatment.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100136"},"PeriodicalIF":0.0,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143680936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of a technology enhanced breast multidisciplinary cancer conference","authors":"Quratulain Sabih ,&nbsp;Opuruiche Ibekwe ,&nbsp;Carmelo Gaudioso ,&nbsp;Kristopher M. Attwood ,&nbsp;Ellis G. Levine ,&nbsp;Stephen B. Edge ,&nbsp;Chukwumere E. Nwogu","doi":"10.1016/j.soi.2025.100135","DOIUrl":"10.1016/j.soi.2025.100135","url":null,"abstract":"<div><h3>Background</h3><div>Multidisciplinary cancer conferences (MCCs) are the standard approach for managing complex breast cases and technology can facilitate these meetings. The objectives of this study were to assess the impact of technology on quality of patient information, case deliberation, and various outcome measures.</div></div><div><h3>Methods</h3><div>We conducted a prospective study from September 2020 to February 2022, before and after implementation of a digital platform for tumor boards. We collected observational and survey data to assess its impact on quality of breast MCC case presentation and discussion. We also reviewed medical records to compare outcomes including rate of change in care plans, compliance of care plans with national guidelines, concordance of treatment received with MCC recommendations and time from MCC presentation to treatment. Comparisons were made using the Mann-Whitney U and Fisher’s exact tests.</div></div><div><h3>Results</h3><div>There were 39 pre- and 47 post-digital platform patient cases. We found that implementation of technology led to an improvement in the quality of the MCCs (median composite scores: 56.9 vs 68.4; p &lt; 0.001). Specific components significantly improved included case history, reason for presentation, radiology and pathology presentations, and medical oncology contribution to case discussions (mean scores: 3.4 vs 3.9, 3.3 vs 3.9, 2.7 vs 4.1, 3.1 vs 4.2; (p &lt; 0.001), &amp; 3.7 vs 4.1; p = 0.05). There was also an improvement in the frequency of arrival at consensus (71.8 % vs 95.7 %; p &lt; 0.012).</div></div><div><h3>Conclusion</h3><div>A tumor board digital platform was shown to improve the quality of presented patient information, physician engagement, and arrival at consensus at multidisciplinary breast cancer conferences.</div></div><div><h3>Synopsis</h3><div>Multidisciplinary cancer conferences (MCCs) play an important role in breast cancer management. We evaluated the impact of a tumor board-specific technology on the quality of breast MCCs and subsequent care. We found that technology improved the quality of information presented and physician engagement.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100135"},"PeriodicalIF":0.0,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143739314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}